Over the past two decades, the company has facilitated the participation of more than 2.6 million patients in 4,000 clinical trials, testing over 1,000 potential drugs in various therapeutic areas. These impressive figures illustrate Clario's considerable impact in a sector where the efficiency, safety and flexibility of clinical trials have become essential.
A technology leader for clinical trials
Founded with a clear vision of modernizing and decentralizing clinical data collection, Clario has been developing tools to enable patients to participate in trials outside traditional clinical centers since the early 2000s. The company anticipated a growing demand for solutions offering greater flexibility to patients and sponsors, a need that exploded during the COVID-19 pandemic.
Today, with nearly 20 years of expertise, Clario offers a complete range of remote data collection technologies, including eCOA (Electronic Clinical Outcome Assessments), medical imaging, cardiac safety, respiratory monitoring and precision movement. This integrated approach enables Clario to position itself as a single-source provider, reducing complexity for laboratories and sponsors who need to manage multiple technologies as part of their clinical studies.
Impressive figures
- Over 2.6 million patients have participated in remote clinical trials using Clario technologies, overcoming geographical and inclusion barriers.
- Over 1,000 compounds have been tested, contributing to therapeutic innovation in numerous fields such as oncology, respiratory diseases and neurological disorders.
- 4,000 clinical trials have been carried out using Clario's decentralized and hybrid solutions, demonstrating the confidence of major pharmaceutical companies in these technologies.
- Nearly 20 years of leadership in remote data collection, a longevity that testifies to Clario's commitment to providing reliable, scalable solutions.
A complete, integrated technology platform
One of Clario's key strengths is its technology platform, which centralizes various clinical data collection tools. Unlike other suppliers, Clario offers a single solution covering a multitude of modalities, enabling sponsors to optimize their processes while reducing the number of technology partners involved in studies. This ability to simplify the technological landscape is a major asset for its customers, who are looking for efficiency and consistency in their trials.
A promising future with over 19,000 tests performed
With a global presence covering 30 facilities in nine countries, and a team of experts combining scientific, technological and operational skills, Clario has contributed to the completion of over 19,000 clinical trials. These studies have led to 870 regulatory approvals, involving over 5 million patients in 120 countries. This history of innovation positions Clario as a key player in the evolution of clinical trials and pharmaceutical research worldwide.
Growing demand for efficiency and diversity
As sponsors and regulators strive to improve patient diversity in clinical trials, Clario is at the forefront of meeting this need. Its DCT technologies not only make it easier to recruit patients from different parts of the world, but also reduce the complexity associated with participation, a significant advance in a sector where inclusion and accessibility have become priorities.
Clario continues to transform the clinical trials landscape through its technological expertise and commitment to innovation. With an integrated platform covering a comprehensive range of solutions, the company strives to make trials more accessible, efficient and diverse.
Why did Nordic Capital want to invest in the company? And how will it create value? Answers from Klas Tikkanen, Chief Operating Officer of Nordic Capital.
